BioNTech Q3 2026 Earnings

Adjusted EPS: 1.76 - Revenue: 1.29B (est 1.02B) - Operating Income: 125.0M - Sees FY Revenue: 1.70B To 1.90B (previously 1.60B To 1.90B) - Still Sees FY SG&A Expense: 700M To 800M (est 761.1M) - Still Sees FY R&D Expenses: 2.00B To 2.30B